Advancing the Power of
Targeted Therapies
Significantly Improving Upon the Delivery, Safety and Performance of Existing and
Novel Cancer Therapeutics.
Transforming Cancer Therapy
NanoValent Pharmaceuticals is a privately-held company, collaborating closely US-based and international academic and industry partners. We’re dedicated to creating novel treatment options designed to bring us closer to a potential cure for hard to treat cancers and hematological malignancies.
Novel Format Conjugates
Using our unique, highly optimized Hybrid Polymerized Liposomal Nanoparticle (HPLN) platform technology, we create Novel Format Conjugates called nano-ADC like Targeted Nanosphers (nADC/TNS). These targeted agents significantly improve the delivery, safety and efficacy of both existing and novel anti-cancer therapeutics
Highly Flexible Technology
nADCs/TNS are created using our highly flexible platform technology. The power of this platform technology is best demonstrated by our lead investigational product, NV103, which is approaching potential IND status with strong data in CD99 expressing tumor models, including glioblastoma (GBM), pancreatic, ovarian cancer and Ewing sarcoma.
Innovative Medicine
Based on our unique platform technology, we develop novel, targeted drugs that more precisely target malignant cells while sparing normal, healthy tissues. Due to their capacity to cross the blood-brain barrier (BBB), nano-ADCs like Targeted Nanospheres (nADC/TNS), based on our platform technology, can be applied beyond oncology, including neurology.
Unmet Medical Needs
Despite important advances in available treatments for oncological and hematological malignancies, there remain unmet medical needs requiring the development of novel targeted therapies.
Unlocking the power of these therapies, including antibody-drug conjugates (ADCs), has resulted in novel tools, allowing tumor specific targeting. However, the performance of these targeted therapeutics remains limited, resulting in many patients unable to benefit.
Our Pipeline
Using our unique, highly optimized Hybrid Polymerized Liposomal Nanoparticle (HPLN) platform technology, we have developed tumor-specific targeted novel format conjugates called nano-ADCs like Targeted Nanospheres (nADC/TNS) which combine drug-loaded nanoparticles with the targeting ability of monoclonal antibodies. The resulting technology offers several significant advantages over existing untargeted and targeted therapies.
Our Investigational Drug Candidates
NanoValent Pharmaceuticals has developed five HPLN (Hybrid Polymerized Liposomal Nanoparticle) based nano-ADCs likeTargeted Nanospheres (nADC/TNS) candidates in oncology.
NV101 (Doxorubicin; anti-CD99)
Validating programs with NV101 in Ewing sarcoma and other CD99 expressing tumors are planned.
NV102 (Doxorubicin; anti-CD19)
Validating programs with NV102 in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and other CD19 expressing tumors are planned.
NV103 (Irinotecan; anti-CD99)
NV103, our lead product, is now approaching Investigational News Drug Application (IND) status and is being validated in CD99 expressing tumors, including glioblastoma (GBM), ovarian cancer, pancreatic cancer, and Ewing sarcoma.
NV104 (Irinotecan; anti-B7H3)
Validating programs with NV104 in glioblastoma (GBM) and other B7H3 (CD276) expressing tumors are planned.
NV105 (temozolomide; anti-B7H3)
Validating programs with NV105 in glioblastoma (GBM) and and other B7H3 (CD276) expressing tumors are planned.
Our Science
Outperforming ADCs
Our Platform technology allows for preferentially delivery of cytotoxic drugs to cancer cells while sparing normal, healthy cells and tissue.
At the same time the technology delivers a lower systemic cytotoxic dose to minimize both initial and long-term morbidity. Improving on the high tumor specificities already seen with ADCs, our novel format nano-ADC like Targeted Nanosphers (nADC/TNS) provide a significantly greater on-target drug-to-antibody ratio (DAR) than traditional ADCs.
Furthermore, the polyvalency of multiple antibodies attached to a single nADC/TNS enhances the overall avidity of nanoparticles to target tumor cells, compared to a single ADC. Finally, the cytotoxic agents inside the hollow-shell nanoparticle are not chemically conjugated to the carrier. Once released from the carrier, no in situ chemical decoupling is required for the drug to become fully bioavailable.